Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 17/20 | 0.47 |
| ▸ | JAK1 known ✓ | P23458 | 16/20 | 0.47 |
| ▸ | JAK3 known ✓ | P52333 | 10/20 | 0.47 |
| ▸ | TYK2 known ✓ | P29597 | 5/20 | 0.47 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.40 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 3/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | CIT | O14578 | 2/20 | 0.40 |
| ▸ | GAK | O14976 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL1498772 | 1.00 | JAK2 (0.47) | JAK2JAK1JAK3TYK2HDAC6 | |
| SCHEMBL1498869 | 0.96 | JAK2 (0.48) | JAK2JAK1JAK3TYK2HDAC6 | |
| SCHEMBL2085646 | 0.87 | JAK2 (0.47) | JAK2JAK1JAK3TYK2HDAC6 | |
| SCHEMBL1498831 | 0.87 | TYRO3 (0.47) | JAK2JAK1JAK3TYK2HDAC6 | |
| SCHEMBL2084638 | 0.85 | TYRO3 (0.57) | JAK2JAK1JAK3TYK2HDAC6 | |
| SCHEMBL1499062 | 0.79 | JAK2 (0.47) | JAK2JAK1JAK3TYK2HDAC6 | |
| SCHEMBL1499140 | 0.78 | JAK2 (0.48) | JAK2JAK1JAK3TYK2HDAC6 | |
| SCHEMBL12780536 | 0.78 | JAK2 (0.47) | JAK2JAK1JAK3TYK2HDAC6 | |
| SCHEMBL2086283 | 0.78 | JAK2 (0.43) | JAK2JAK1JAK3TYK2HDAC6 | |
| SCHEMBL1499221 | 0.78 | JAK2 (0.48) | JAK2JAK1JAK3TYK2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| WO-2011028685-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.